

Robert K LeÅ>niak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6564940/publications.pdf>

Version: 2024-02-01

9
papers

135
citations

1684188

5
h-index

1720034

7
g-index

10
all docs

10
docs citations

10
times ranked

209
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with inÂvivo efficacy. European Journal of Medicinal Chemistry, 2022, 229, 114080.	5.5	19
2	Imitation of $\hat{1}^2$ -lactam binding enables broad-spectrum metallo- $\hat{1}^2$ -lactamase inhibitors. Nature Chemistry, 2022, 14, 15-24.	13.6	39
3	Discovery of 1<i>H</i>-</i>Pyrazole Biaryl Sulfonamides as Novel G2019S-LRRK2 Kinase Inhibitors. ACS Medicinal Chemistry Letters, 2022, 13, 981-988.	2.8	6
4	¹⁹F NMR studies on $\hat{1}^3$ -butyrobetaine hydroxylase provide mechanistic insights and suggest a dual inhibition mode. Chemical Communications, 2019, 55, 14717-14720.	4.1	4
5	The Jumonji-C oxygenase JMJD7 catalyzes (3S)-lysyl hydroxylation of TRAFAC GTPases. Nature Chemical Biology, 2018, 14, 688-695.	8.0	31
6	Human carnitine biosynthesis proceeds via (2S,3S)-3-hydroxy-N^{$\hat{1}\mu$}-trimethyllysine. Chemical Communications, 2017, 53, 440-442.	4.1	11
7	Cationâ€œ Interactions Contribute to Substrate Recognition in $\hat{1}^3$ â€œButyrobetaine Hydroxylase Catalysis. Chemistry - A European Journal, 2016, 22, 1270-1276.	3.3	24
8	Frontispiece: Cationâ€œ Interactions Contribute to Substrate Recognition in $\hat{1}^3$ â€œButyrobetaine Hydroxylase Catalysis. Chemistry - A European Journal, 2016, 22, .	3.3	0
9	Targeting LRRK2 mutations in Parkinson's disease. Future Medicinal Chemistry, 0, , .	2.3	1